WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 585225
CAS#: 33419-68-0
Description: Safrazine is a hydrazinic MAO inhibitor.
MedKoo Cat#: 585225
Name: Safrazine
CAS#: 33419-68-0
Chemical Formula: C11H16N2O2
Exact Mass: 208.1212
Molecular Weight: 208.261
Elemental Analysis: C, 63.44; H, 7.74; N, 13.45; O, 15.36
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Safrazine; Safrasin; Saphrazine
IUPAC/Chemical Name: Hydrazine, (1-methyl-3-(3,4-(methylenedioxy)phenyl)propyl)-
InChi Key: IBWPUTAKVGZXRB-UHFFFAOYSA-N
InChi Code: InChI=1S/C11H16N2O2/c1-8(13-12)2-3-9-4-5-10-11(6-9)15-7-14-10/h4-6,8,13H,2-3,7,12H2,1H3
SMILES Code: NNC(C)CCC1=CC(OCO2)=C2C=C1
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 208.261 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
1: Orikasa S, Kisara K. [Effects of parasympathetic drugs on head-twitch response induced by tyramine (author's transl)]. Nihon Yakurigaku Zasshi. 1981 May;77(5):477-82. Japanese. PubMed PMID: 7197657.
2: Yokoyama T, Karube T, Iwata N. Comparative studies of the effects of RS-8359 and safrazine on monoamine oxidase in-vitro and in-vivo in mouse brain. J Pharm Pharmacol. 1989 Jan;41(1):32-6. PubMed PMID: 2565961.
3: Eto S, Noda H, Minemoto M, Noda A. Effect of safrazine, a monoamine oxidase inhibitor bearing a hydrazine-terminal, on phenytoin metabolism in isolated rat hepatocytes. Chem Pharm Bull (Tokyo). 1988 Jan;36(1):456-8. PubMed PMID: 3378307.
4: Ogata K, Nakayama T, Kawai M. [Treatment of nocturnal periodic hypoxemia with safrazine hydrochloride in a patient with Duchenne muscular dystrophy under nasal intermittent positive pressure ventilation]. Rinsho Shinkeigaku. 1998 Aug;38(8):776-8. Japanese. PubMed PMID: 9916528.
5: Hamada H, Saito T, Torii J. [A case of optico-neuropathy due to the treatment with monoamine oxidase inhibitor (safrazine) (author's transl)]. Rinsho Shinkeigaku. 1979 Jun;19(6):379-87. Japanese. PubMed PMID: 477139.
6: Orikasa S, Sakurada S, Kisara K. Head-twitch response induced by tyramine. Psychopharmacology (Berl). 1980 Jan;67(1):53-9. PubMed PMID: 6245422.
7: Fukushima N. [Role of brain biogenic amines in the central thermoregulatory mechanism of the rat (author's transl)]. Hokkaido Igaku Zasshi. 1975 Jul;50(4):369-85. Japanese. PubMed PMID: 1240080.
8: Inoue T, Izumi T, Honma H, Ohmori T, Denda K, Kasahara T, Koyama T. [Survey and treatment strategy of antidepressant-resistant depression]. Seishin Shinkeigaku Zasshi. 1996;98(5):329-42. Japanese. PubMed PMID: 8741286.
9: Semba J, Nankai M, Maruyama Y, Kaneno S, Watanabe A, Takahashi R. Increase in urinary beta-phenylethylamine preceding the switch from mania to depression: a "rapid cycler". J Nerv Ment Dis. 1988 Feb;176(2):116-9. PubMed PMID: 3339341.
10: Orikasa S, Kisara K. A possible mechanism of the tyramine-induced head-twitch response. Eur J Pharmacol. 1982 May 21;80(2-3):163-9. PubMed PMID: 6213417.
11: KANEKO Z, TANIMUKAI H, NISHINUMA K, NISHIMURA T. Beta-piperonylisopropylhydrazine, a new monoamine oxidase inhibitor as an antidepressant. Psychosomatics. 1963 Mar-Apr;4:99-103. PubMed PMID: 13962210.
12: Mato M, Ookawara S, Aikawa E, Kawasaki K. Studies on fluorescent granular perithelium (F.G.P.) of rat cerebral cortex - especially referring to morphological changes in aging. Anat Anz. 1981;149(5):486-501. PubMed PMID: 6974517.
13: Inui M, Azuma H, Nishimura T. The effect of monoamine oxidase inhibitor and amine precursors on epileptic seizures. Med J Osaka Univ. 1980 Mar;30(3-4):79-85. PubMed PMID: 6774223.
14: Hiramatsu M. Brain monoamine levels and E1 mouse convulsions. Folia Psychiatr Neurol Jpn. 1981;35(3):261-6. PubMed PMID: 6173293.
